Medical Therapy for Asthma: Updates from the NAEPP Guidelines
Am Fam Physician. 2010 Nov 15;82(10):1242-1251.
This is part II of a two-part article on asthma management guidelines. Part I appeared in the May 1, 2009 issue of AFP.
Patient information: See related handouts on this topic at http://familydoctor.org/familydoctor/en/diseases-conditions/asthma.html.
Proper care of patients with asthma involves the triad of systematic chronic care plans, self-management support, and appropriate medical therapy. Controller medications (inhaled corticosteroids, long-acting beta2 agonists, and leukotriene receptor antagonists) are the foundation of care for persistent asthma and should be taken daily on a long-term basis to achieve and maintain control of symptoms. Inhaled corticosteroids are the preferred controller medication; studies have demonstrated that when inhaled corticosteroids are used consistently, they improve asthma control more effectively than any other single long-term control medication. Combining long-acting beta2 agonists and inhaled corticosteroids is effective and safe when inhaled corticosteroids alone are insufficient, and such combinations are an alternative to increasing the dosage of inhaled corticosteroids. For patients with mild persistent asthma, leukotriene receptor antagonists are an alternative, second-line treatment option. They are easy to use, have high rates of compliance, and can provide good symptom control in many patients. Leukotriene receptor antagonists can also be used as an adjunctive therapy with inhaled corticosteroids, but for persons 12 years and older the addition of long-acting beta2 agonists is preferred. Inhaled short-acting beta2agonists are the most effective therapy for rapid reversal of airflow obstruction and prompt relief of asthmatic symptoms. Increasing the use of short-acting beta2agonists or using them more than two days per week or more than two nights per month generally indicates inadequate control of asthma and the need to initiate or intensify anti-inflammatory therapy. Oral systemic corticosteroids should be used to treat moderate to severe asthma exacerbations.
Advances in medical therapy have greatly increased the options for the care of patients with asthma. However, inadequate medical therapy for asthma is still one of the most common reasons for patients to seek unplanned care.1 Each year, despite the availability of a wide and effective array of asthma treatments, patients with asthma make approximately 1.8 million visits to emergency departments, 2 with a fivefold greater rate among blacks than among whites.3 The rate of asthma-related deaths is two per 100,000 population per year, and has not changed since 1995.4 In one study of emergency department visits for asthma, chronic underuse of appropriate medication was apparent among many patients.5 Proper asthma care involves the triad of systematic chronic care plans, support for self-management of asthma, and appropriate medical therapy.6 In this article, we examine the recommendations for medical therapy of asthma from the Expert Panel Report 3 (EPR-3) of the National Asthma Education and Prevention Program (NAEPP).7
SORT: KEY RECOMMENDATIONS FOR PRACTICE
SORT: KEY RECOMMENDATIONS FOR PRACTICE
|Clinical recommendation||Evidence rating||References||Comments|
Inhaled corticosteroids are the most potent and consistently effective long-term control medication for asthma.
Multiple RCTs, meta-analyses
Oral systemic corticosteroids are recommended for moderate to severe asthma exacerbations.
Leukotriene receptor antagonists are an alternative, although not preferred, treatment option for mild persistent asthma (step 2 care; Figure 1). They can also be used as an adjunctive therapy with inhaled corticosteroids, but for patients 12 years and older they are not the preferred adjunctive therapy when compared with the addition of long-acting beta2 agonists.
RCTs, cohort studies; leukotriene receptor antagonists may be more effective in some patients because of better compliance
Long-acting beta2 agonists are not recommended for use as monotherapy for long-term control of persistent asthma.
For patients who have asthma not sufficiently controlled with inhaled corticosteroids alone, the option to increase the dosage of inhaled corticosteroids should be given equal weight to the option of adding long-acting beta2 agonists to inhaled corticosteroids.
Long-acting beta2 agonists are used as an adjunct to inhaled corticosteroid therapy for providing long-term control of symptoms. Of the adjunctive therapies available, long-acting beta2 agonists are the preferred medication to combine with inhaled corticosteroids in persons 12 years and older.
Increasing the use of short-acting beta2agonists or using them more than two days per week for symptom relief (not for prevention of exercise-induced bronchospasm) generally indicates inadequate control of asthma and the need to initiate or intensify anti-inflammatory therapy.
RCTs; use of short-acting beta2 agonists is one of the key warning signs in all control tools (ACT, ATAQ)
ACT = Asthma Control Test; ATAQ = Asthma Treatment Assessment Questionnaire; RCT = randomized controlled trial.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, diseaseoriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.
Long-Term Control Medications
Control medications are the foundation of care for persistent asthma and should be taken daily on a long-term basis to achieve and maintain control of symptoms. The major medications are inhaled corticosteroids, leukotriene receptor antagonists, and long-acting beta2 agonists. There is a difference of opinion about calling long-acting beta2agonists “controllers” because when used by themselves, they can be associated with increases in asthma exacerbations and death.8 For the purposes of this article, we will retain the current terminology as used in the EPR-3 guidelines.
Studies have shown that when inhaled corticosteroids are used consistently, they improve asthma symptoms more effectively than any other single long-term control medication in both children and adults.7 Patients with mild to moderate persistent asthma treated with inhaled corticosteroids demonstrate improved symptom scores, lower exacerbation rates, and reduced symptom frequency. They also use fewer supplemental short-acting beta2 agonists, take fewer courses of oral systemic corticosteroids, and have fewer hospitalizations, compared with patients taking other single long-term control medications.9
There are no clinically meaningful differences among the various types of inhaled corticosteroids. Bronchoprotective effects of inhaled corticosteroids delivered via dry powder inhaler and hydrofluoroalkane- propelled metered dose inhalers are equivalent.10,11 When used correctly, metered dose inhalers deposit 20 to 30 percent of the dose in the lungs. The use of spacers (more properly termed “valved holding chambers”) markedly increases this percentage.12
There are clinically significant differences in sensitivity and responsiveness to inhaled corticosteroid therapy. This may be related to high levels of inflammation or reduced corticosteroid sensitivity.13 Smokers have a decreased responsiveness to steroids, possibly because of persistent irritation and scarring.14,15 Black children may have an increased risk of corticosteroid insensitivity because of deficiencies in T cell pathways.16,17
Systemic effects of inhaled corticosteroids may occur but typically are not clinically important, except with long-term, high-dose use. Adding a spacer device or changing either the inhaled corticosteroid medication or the delivery system can usually overcome asthma-related cough. Dysphonia, generally intermittent, is thought to be caused by laryngeal edema and mucosal thickening or possibly myopathy.18 It typically resolves with temporary cessation of the medication, but may also resolve with a change from a dry-powder inhaler to a metered dose inhaler with spacer.
Because of their delayed onset of action, inhaled steroids are insufficient for moderate to severe exacerbations.7 Instead, oral steroid treatment is recommended: 1 to 2 mg per kg per day for three to 10 days in children, or 40 to 60 mg per day in one or two divided doses for five to 10 days in adults. Tapering is not necessary.19
LEUKOTRIENE RECEPTOR ANTAGONISTS
There are two widely available leukotriene receptor antagonists: montelukast (Singulair; for patients older than one year) and zafirlukast (Accolate; for patients seven years and older). Montelukast and zafirlukast are appropriate alternative therapies for mild persistent asthma in patients who are unable or unwilling to use inhaled corticosteroids. 7 Leukotriene receptor antagonists have the advantages of ease of use and high rates of compliance,20 and they can provide good control of asthma symptoms in many patients. A recent randomized controlled trial compared fluticasone (Flovent) twice daily, fluticasone/salmeterol (Advair) once daily, and montelukast once daily in children with mild persistent asthma that was well controlled on twice-daily fluticasone. Lung function outcomes improved with the combination therapy, but there were similar results in patient-oriented outcomes among the three arms, and fewer respiratory infections in the montelukast group.21
Montelukast is taken once daily, whereas zafirlukast is used twice daily. For patients 12 years and older, combining leukotriene receptor antagonists and inhaled corticosteroids is an alternative for moderate persistent asthma, but studies of this combination have been limited. Leukotriene receptor antagonists are indicated in exercise-induced bronchospasm and can improve the condition in up to 50 percent of patients. They are the treatment of choice for aspirin-sensitive asthma.7,22
Leukotriene receptor antagonists are an alternative, although not preferred, treatment option for mild persistent asthma (step 2 care; Figure 17). They can also be used as an adjunctive therapy with inhaled corticosteroids, but for patients 12 years and older they are not the preferred adjunctive therapy compared with the addition of long-acting beta2 agonists.7,23,24
LONG-ACTING BETA2 AGONISTS
Salmeterol (Serevent) and formoterol (Foradil) are bronchodilators that have a duration of action of more than 12 hours. They are very specific for β2-adrenergic receptors and, thus, have low rates of tremor and palpitations or tachycardia.23 Regular use of long-acting beta2 agonists results in only mild tachyphylaxis to the maximal bronchodilator effect and the duration of action of these drugs. However, the bronchoprotective effect of long-acting beta2 agonists (e.g., inhibition of exercise-induced bronchoconstriction) rapidly wanes with regular use.24,25 In general, the effectiveness of short-acting beta2 agonists is not impaired in regular users of long-acting beta2 agonists.26 In some ethnic populations, most notably blacks, there may be genetic variations in the β2-adrenergic receptor that may reduce the effectiveness of long-acting beta2 agonists, although more recent research has called this into question.27–29
There have been concerns about the safety of long-acting beta2 agonists in children and adults, with an increase in severe exacerbations and deaths when added to usual asthma therapy.8 This has prompted the U.S. Food and Drug Administration to review these medications and add a new warning labeling. Available data strongly suggest that long-acting beta2 agonists should never be used as monotherapy for long-term control of persistent asthma7; they should be used only in combination therapy, and increasing the dose of inhaled corticosteroids should be given equal weight to the option of adding a long-acting beta2 agonist if the initial dosage of inhaled corticosteroids is not effective.7,12
CROMOLYN SODIUM AND NEDOCROMIL
Cromolyn sodium and nedocromil stabilize mast cells and interfere with chloride channel function. They are an alternative, but not preferred, medication for the treatment of mild persistent asthma. With newer agents available, their use has markedly decreased.
Omalizumab (Xolair) is a monoclonal antibody that prevents binding of immunoglobulin E (IgE) to the high-affinity receptors on basophils and mast cells. It has been shown to reduce the need for both oral and inhaled steroids (number needed to treat [NNT] = 6 to 12).30 A reduction in protocol-defined exacerbations was observed in approximately 15 percent of patients (NNT = 6).31 Omalizumab is used as additive therapy for patients 12 years and older with severe persistent asthma who have demonstrated immediate hypersensitivity to inhaled allergens. Anaphylaxis may occur in patients receiving this medication. Usual dosages range from 150 to 375 mg administered subcutaneously every two to four weeks, depending on IgE level and patient weight. The approximate retail price is $738 for a 150-mg vial.32,33 Because of the required monitoring and side effects involved in its use, omalizumab therapy should probably be instituted only in collaboration or consultation with an asthma subspecialist.
Sustained-release theophylline is a mild to moderate bronchodilator used as an alternative, although not preferred, adjunctive therapy with inhaled corticosteroids. Theophylline may have mild anti-inflammatory effects. Monitoring of serum theophylline concentration is essential. Theophylline still has a role as add-on therapy in some clinical situations.7
Numerous studies have demonstrated excellent control of moderate persistent asthma with combination therapy in patients 12 years and older.7 Combination therapy has not been studied in children younger than four years. Strong evidence in patients 12 years and older indicates that the combination of inhaled corticosteroids and longacting beta2 agonists leads to clinically meaningful improvements in lung function and symptoms and a reduced need for quickrelief short-acting beta2 agonists. Adding a leukotriene receptor antagonist or theophylline to inhaled corticosteroids or doubling the dose of inhaled corticosteroids also improves outcomes, but the evidence is not as substantial as with the addition of long-acting beta2 agonists.34,35
Step-down strategies in combination therapy may mean changing to a new device with a lower dose of inhaled steroid, which can result in having two combination devices and two co-pays. However, a recent study showed that reducing the frequency of fluticasone/salmeterol therapy to once-daily dosing maintained good control of asthma symptoms.21
Finally, a study published after the EPR-3 guidelines compared continuous therapy with inhaled corticosteroids plus as-needed short-acting beta2 agonists with as-needed use only of inhaled corticosteroids plus short-acting beta2 agonists during exacerbations for patients with mild persistent asthma. The researchers found similar clinical outcomes over a six-month period, with a lower total steroid dose in the as-needed dosing group.36
INHALED SHORT-ACTING BETA2 AGONISTS
Short-acting beta2 agonists are the most effective therapy for rapid reversal of airflow obstruction and prompt relief of asthmatic symptoms. Albuterol, levalbuterol (Xopenex), and pirbuterol (Maxair) are the most commonly used short-acting beta2 agonists in the United States. Short-acting beta2 agonists have an onset of action of five minutes or less, peaking within 30 to 60 minutes, and a duration of action of four to six hours.37 Regular use (i.e., four or more times daily) does not affect potency but is associated with a reduction in the duration of action.38,39
EPR-3 recommends using short-acting beta2 agonists only as needed for relief of symptoms or before anticipated exposure to known asthmatic triggers (e.g., animals, exercise). Puffs can be taken in 10- to 15-second intervals; longer intervals offer no benefits.40 Increasing the use of shortacting beta2 agonists or using them more than two days per week for symptom relief (not for prevention of exercise-induced bronchospasm) generally indicates inadequate control of asthma and the need to initiate or intensify anti-inflammatory therapy.7
Tremor, anxiety, heart pounding, and tachycardia (but not hypertension) are common dose-dependent side effects. Some patients are highly sensitive to short-acting beta2 agonists, but most tolerate them well. Beta blockers may diminish the effectiveness of short-acting beta2 agonists but are not contraindicated.41,42
Levalbuterol, the R-enantiomer of albuterol, has an effectiveness and side effect profile indistinguishable from that of the racemic mixture of molecules in albuterol, but is more expensive (one inhaler: $54 for levalbuterol versus $40 to $55 for albuterol). Standard doses for each are two puffs every two to six hours as needed.33,43,44
Metered dose inhalers are the delivery mechanism for all short-acting beta2 agonists. There has been a recent change to all hydrofluoroalkane propellants with the exception of pirbuterol.45 The new inhalers have a different “feel” of the spray, and many patients have reported that they did not think they were getting the full dose of medication. However, the potency of hydrofluoroalkane inhalers is equal to that of chlorofluorocarbon-propelled inhalers.46 Use of spacers is still encouraged.47 It is recommended that physicians observe and regularly review patients' inhaler use, because many if not most patients have difficulty with proper inhalation technique.
In many settings, metered dose inhalers with spacers may be more acceptable and less costly than nebulizer treatment. Bronchodilation by short-acting beta2 agonists delivered with a spacer is comparable to nebulized albuterol when a sufficient number of puffs are administered and inhalation technique is good.48 Most studies showing comparable effects of nebulizers and spacers in emergency department settings used six to 10 puffs from a metered dose inhaler (each puff given sequentially).7 As most health care professionals have recognized, two puffs are not equivalent to a nebulizer treatment.
ORAL SHORT-ACTING BETA2 AGONISTS
Oral short-acting beta2 agonists are less potent, take longer to act, and have more side effects compared with inhaled shortacting beta2 agonists.49 Their use is strongly discouraged. Anticholinergic bronchodilators, such as ipratropium (Atrovent), are not recommended as monotherapy for quick relief of asthmatic symptoms. They have a longer onset of action (20 to 30 minutes) and cause less bronchodilation than inhaled beta2 agonists.50 Anticholinergic agents combined with short-acting beta2 agonists, however, may be beneficial in treating severe asthmatic attacks or those induced by beta blockers.51
Using Asthma Medications Wisely
Clinical trials have had mixed findings on the effect of action plans on clinical asthma outcomes, but the consensus is that education in asthma self-management involving self-monitoring by peak expiratory flow or symptoms, coupled with regular medical review and a written action plan, improves health outcomes for patients with asthma52–54 (Figures 2 and 355).
For initiation of maintenance care, two approaches are low-dose and high-dose strategies. In either strategy, a critical element is assessing both severity and control as outlined in the EPR-3 (Figure 17). Low-dose strategies involve using a low-dose inhaled steroid or leukotriene receptor antagonist with asneeded short-acting beta2 agonists to gradually attain control within a two-week period. This approach is appropriate for patients with mild symptoms and no recent acute events.
A high-dose strategy (treating with higher-dose inhaled steroids or combination agents, usually a step higher than their severity assessment to achieve rapid control) can be used initially and then reduced (stepped down) as control is achieved. Follow-up should be scheduled within two weeks to assess initial response; if low-dose therapy does not provide adequate control, a step up is indicated. High-dose therapy, if effective, should be continued for three months before considering a step down in therapy.
Planned follow-up visits for patients with persistent asthma should occur at least twice yearly, and more often for those with moderate to severe persistent asthma. Some of these visits can be combined with health maintenance care, with others scheduled before patients' most symptomatic seasons. Planned care visits should be used as an opportunity to review use of delivery devices, action plans, and triggers. Care can be stepped down if patients are consistently doing well, based on spirometry and control assessment (e.g., with the Asthma Control Test or Asthma Treatment Assessment Questionnaire).7
1. Popa V. Emergency department visits in asthma: should all be prevented? Chest. 2001;120(4):1058–1061.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326(13):862–866.
3. Centers for Disease Control and Prevention. National surveillance for asthma–United States, 1980–2004. MMWR Morb Mortal Wkly Rep. 2007;56(SS-8):43.
4. Dales RE, Schweitzer I, Kerr P, Gougeon L, Rivington R, Draper J. Risk factors for recurrent emergency department visits for asthma. Thorax. 1995;50(5):520–524.
5. Akinbami L. Office of Analysis and Epidemiology, Centers for Disease Control and Prevention Asthma prevalence, health care use and mortality: United States, 2003–05. November 2006. http://www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05.htm. Accessed April 1, 2009.
6. Fredrickson DD, et al. Understanding frequent emergency room use by Medicaid-insured children with asthma: a combined quantitative and qualitative study. J Am Board Fam Pract. 2004;17(2):96–100.
7. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Heart, Lung, and Blood Institute; Revised August 2007. NIH publication no. 07-4051. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed May 10, 2009.
8. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol [published correction appears in Chest. 2006; 129(5):1393]. Chest. 2006;129(1):15–26.
9. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063.
10. Lipworth BJ, Sims EJ, Das SK, Morice AH, O'Connor BJ. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol. 2005;95(3):283–290.
11. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510–516.
12. Dolovich MB, Ahrens RC, Hess DR, et al.; American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371.
13. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111(1):3–22.
14. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230.
15. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308–1311.
16. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998;101(5):594–601.
17. Federico MJ, Covar RA, Brown EE, Leung DY, Spahn JD. Racial differences in T-lymphocyte response to glucocorticoids. Chest. 2005;127(2):571–578.
18. DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluticasone therapy. Arch Otolaryngol Head Neck Surg. 2002;128(6):677–681.
19. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet. 1993;341(8841):324–327.
20. Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147(2):213–220.
21. Peters SP, Anthonisen N, Castro M, et al.; American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma [published correction appears in N Engl J Med. 2007;357(7):728]. N Engl J Med. 2007;356(20):2027–2039.
22. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14.
23. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327(20):1420–1425.
24. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339(3):141–146.
25. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99(5):655–659.
26. Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ. 1993;306(6877):543–545.
27. Wechsler ME, Lehman E, Lazarus SC, et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519–526.
28. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370(9605):2118–2125.
29. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008;24(6):1669–1682.
30. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published correction appears in Eur Respir J. 2001;18(4):739–740]. Eur Respir J. 2001;18(2):254–261.
31. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti- IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190.
32. Xolair. Drugs.com. http://www.drugs.com/xolair.html. Accessed August 18, 2010.
33. Red Book. Montvale, N.J.: Medical Economics Data; 2010.
34. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153(5):1481–1488.
35. Pauwels RA, Löfdahl CG, Postma DS, et al.; Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma [published correction appears in N Engl J Med. 1998;338(2):139]. N Engl J Med. 1997;337(20):1405–1411.
36. Papi A, Canonica GW, Maestrelli P, et al.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040–2052.
37. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333(8):499–506.
38. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989;140(3):586–592.
39. Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest. 1984;85(1):34–38.
40. Lawford P, McKenzie D. Pressurized aerosol inhaler technique: how important are inhalation from residual volume, inspiratory flow rate and the time interval between puffs? Br J Dis Chest. 1983;77(3):276–281.
41. Doshan HD, Rosenthal RR, Brown R, Slutsky A, Applin WJ, Caruso FS. Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. J Cardiovasc Pharmacol. 1986;8(suppl 4):S105–S108.
42. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–725.
43. Levalbuterol. Drugs.com. http://www.drugs.com. Accessed September 9, 2010.
44. Albuterol. Drugs.com. http://www.drugs.com. Accessed September 9, 2010.
45. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med. 2007;356(13):1344–1351.
46. Ramsdell JW, Colice GL, Ekholm BP, Klinger NM. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol. 1998;81(6):593–599.
47. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet. 2004;43(6):349–360.
48. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006;(2): CD000052.
49. Nathan RA. Beta 2 agonist therapy: oral versus inhaled delivery. J Asthma. 1992;29(1):49–54.
50. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987;82(1):59–64.
51. Ducharme FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma. J Pediatr. 1998;133(4):479–485.
52. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003; (1):CD001117.
53. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004;59(2):94–99.
54. Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev. 2006;(3):CD005306.
55. Regional Asthma Management and Prevention, a program of the Public Health Institute. http://www.rampasthma.org/. Accessed September 23, 2010.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions